Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc.

Class action for Canadians prescribed Rexulti who developed compulsive or impulse-control disorders.

A national class action in Canada against Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc. resulted in a $4.75 million settlement approved by Quebec Superior Court. The lawsuit concerns the antipsychotic drug Rexulti, prescribed since February 2017, and its alleged link to compulsive behaviors and impulse-control disorders such as gambling, shopping, or binge-eating. Eligible claimants may receive compensation based on the severity of their condition. The deadline to file claims is August 27, 2026.

You may be eligible if you:

• Canadians prescribed Rexulti since February 2017.
• Those who developed compulsive behaviors or impulse-control disorders such as gambling, shopping, or binge-eating after taking Rexulti.
• Eligibility confirmed through the official claim process.

• Basic contact information
• Dates tied to your purchase or account activity
• Proof of purchase or supporting documents

If you do not have every document, you may still be able to file. Many settlements accept claims without receipts.

• Visit the official claim website.
• Review eligibility criteria and required documentation.
• Submit your claim before the August 27, 2026 deadline.